Skip to main content
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes Care

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes Care
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • Special Article Collections
    • ADA Standards of Medical Care
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • Special Article Collections
    • ADA Standards of Medical Care
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Brief Report

Prevalence of the Metabolic Syndrome Among Adult New Zealanders of Polynesian and European Descent

  1. David Simmons, FRACP, MD1 and
  2. Colin F. Thompson, FRACP2
  1. 1Waikato Clinical School, University of Auckland, Waikato Hospital, Hamilton, New Zealand
  2. 2Mulazmin Medical Center, Omdurman, Khartoum, Sudan
  1. Address correspondence and reprint requests to Prof. David Simmons, Waikato Clinical School, University of Auckland, Waikato Hospital, Private Bag 3200, Hamilton, New Zealand. E-mail: simmonsd{at}waikatodhb.govt.nz
Diabetes Care 2004 Dec; 27(12): 3002-3004. https://doi.org/10.2337/diacare.27.12.3002
PreviousNext
  • Article
  • Figures & Tables
  • Info & Metrics
  • PDF
Loading
  • ATP, Adult Treatment Panel
  • OGTT, oral glucose tolerance test

The metabolic syndrome describes the clustering of risk factors for diabetes and cardiovascular disease (1). New Zealand Polynesians of both Maori and Pacific descent have high rates of conponents for the metabolic syndrome: type 2 diabetes (2), obesity (2), hypertension (3), dyslipidemia (4), and coronary heart disease (5,6). There have been no previous reports of the prevalence of the metabolic syndrome in New Zealand since the release of the Adult Treatment Panel (ATP) III criteria (7). In this study, we compare the prevalence of the metabolic syndrome by ATP III criteria among New Zealanders of European and Polynesian descent.

RESEARCH DESIGN AND METHODS

Residents from a household census in South Auckland were randomly selected using a sampling framework stratified by age, sex, and ethnic group as previously described (2). At each house, questionnaires were completed; weight, height, and waist were measured; and a random venous sample was taken for glucose measurement (into fluoride; spun, chilled, and assayed within 3 h). Those without known diabetes and either a random glucose ≥6.5 mmol/l within 2 h of a meal or ≥6 mmol/l ≥2 h after a meal (defined as “screen positives”), as well as a random control group (28% of other subjects; defined as “screen negatives”) were invited for a 75-g oral glucose tolerance test (OGTT). At the OGTT, fasting samples were also taken for lipids (total, HDL, and LDL cholesterol and triglycerides) and measured on a Hitachi 747 analyzer (Hitachi, Tokyo, Japan) (interassay coefficient of variation 2.2, 4.8, and 3.3%, respectively, except LDL cholesterol, which was calculated using the Friedewald equation). Resting blood pressure was taken as the mean of two measurements using a standard mercury sphygmomanometer (with large cuff where necessary) following a standardized approach and before the 2-h glucose sampling.

The ATP III criteria (2) for the metabolic syndrome were considered to have been met when three or more of the following factors were present: waist circumference >102 cm for men or >88 cm for women, elevated blood pressure (treated hypertension or systolic blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg as mean of two readings), elevated triglycerides (≥1.7 mmol/l), decreased HDL (<1.04 mmol/l for men or <1.29 mmol/l for women), elevated fasting glucose (≥6.1 mmol/l), or diabetes. The study was approved by the University of Auckland Ethics Committee, and subjects gave informed consent.

Randomization and statistics were undertaken using SPSS for Windows (version 12.0; SPSS, Chicago IL). Comparisons of proportions were made using the χ2 test. Calculations of the prevalence of each constituent of the metabolic syndrome by ATP III criteria and overall were made by direct standardization to the proportion of subjects who were screen negative or positive with Excel 2000 (Microsoft) as follows: (screen positive with characteristic at OGTT) × (% screened who were screen positive)/screen positive attending OGTT + (screen negative with characteristic at OGTT) × (% screened who were screen negative)/screen negative attending OGTT.

RESULTS

As previously reported, the initial household survey had a 91% response with 2,737 interviewed, of whom 314 had known diabetes. Of the 2,423 invited to participate without known diabetes, 1,562 (64.5%) were screened in their home. Subsequent attendance at OGTT was 68.4% (327 of 478) among screen-positive and 67.2% (207 of 308 invited) among screen-negative subjects. Mean age was 50 ± 5 (Europeans), 49 ± 5 (Maori), and 49 ± 5 years (Pacific) (P = 0.029) in the 40- to 59-year age-group and 68 ± 6, 66 ± 5, and 67 ± 5 years, respectively, in the 60- to 79-year age-group (P < 0.001).

The prevalence of known diabetes, obesity, and low HDL was significantly higher among Polynesians in both age-groups (Table 1). Maori, but not Pacific, subjects consistently had a higher blood pressure, although this difference was not significant among women aged 60–79 years. The prevalence of hypertriglyceridemia was highest among Maori and Pacific people, except among women aged 40–59 years. The presence of an elevated fasting glucose or new diabetes diagnosis was significantly more likely among Maori and Pacific women aged 40–59 years and nonsignificantly higher among men of these ethnic groups.

Among those aged 40–59 years, a very small proportion of Maori and Pacific subjects showed no components of the metabolic syndrome and a much higher proportion (approximately half) had three or more components, making them eligible for metabolic syndrome diagnosis. Among those aged 60–79 years, there was no significant difference in the overall distribution of the components or prevalence of the metabolic syndrome among women (P = 0.350). The prevalence of the metabolic syndrome was higher among men (P = 0.005).

CONCLUSIONS

Among Maori and Pacific peoples aged ≥40 years, the total prevalence of the metabolic syndrome and known diabetes was >50%, with ∼80% having at least two components of the metabolic syndrome (also associated with a significantly increased risk of cardiovascular disease [8]). The prevalence of the metabolic syndrome by ATP III criteria among men of European descent aged ≥40 years has been reported to range from 12% across the eight DECODE (Diabetes Epidemiology: Collaborative Analysis of Diagnostic Criteria in Europe) studies (8), to 28.8% (35–75 years) in Canada (9), and to 30–40% in the U.S. (10). These New Zealand data are clearly most comparable to those in North America. Among women of European descent in Canada aged 35–75 years, the prevalence of the metabolic syndrome was 14.3% (9), and in Europe, the prevalence increased from 5.2% among those aged 40–49 years to 16.8% among those aged ≥70 years (8). In the U.S., the prevalence of the metabolic syndrome increased from ∼19% among women aged 40–49 years to a peak of ∼45% in those aged 70–79 years (10). There have been no reports of the prevalence of the metabolic syndrome among Polynesians elsewhere, but the age-specific prevalences among Maori and Pacific people were comparable to Mexican Americans (10,11), Arab Americans (12), and Native Americans (9,13) but higher than those among South Asians (9), East Asians (9,14,15), and African Americans (10).

These findings are limited by the small numbers in each stratum and the stratified nature of the attendance at OGTT, and this probably explains the lack of statistical significance for some components (e.g., new diabetes). The criteria for obesity are also an issue among Polynesians (16).

View this table:
  • View inline
  • View popup
Table 1—

Prevalence of the metabolic syndrome by ATP III criteria (three or more items) and its components

Acknowledgments

The authors thank Servier for funding a research fellow (C.F.T.) and the Auckland Medical Research Foundation, the Maurice and Phyllis Paykel Trust, the Hector Trust, and SmithKline Beecham for contributions to the research funding.

The authors also thank members of the Diabetes Projects Trust for their assistance.

Footnotes

  • A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    • Accepted September 2, 2004.
    • Received September 1, 2004.
  • DIABETES CARE

References

  1. ↵
    Zimmet PZ: Kelly West Lecture 199: Challenges in diabetes epidemiology: from West to the rest. Diabetes Care 15:232–252, 1992
    OpenUrlAbstract/FREE Full Text
  2. ↵
    Simmons D, Thompson C, Volklander D: Polynesians: prone to obesity and type 2 Diabetes but not hyperinsulinaemia. Diabet Med 18:1–6, 2001
  3. ↵
    Prior IAM: Cardiovascular epidemiology in New Zealand and the Pacific. NZ Med J 80:245–252, 1974
    OpenUrlPubMed
  4. ↵
    Beaglehole R, Prior IAM, Eyles E, Sampson V: High density lipoprotein cholesterol and other serum lipids in New Zealand Maoris. NZ Med J 90:139–142, 1979
    OpenUrlPubMed
  5. ↵
    Tipene-Leach, Stewart A, Beaglehole R: Coronary heart disease mortality in Auckland Maori and Europeans. NZ Med J 104:55–57, 1991
    OpenUrlPubMed
  6. ↵
    Tukuitonga C, Stewart A, Beaglehole R: Coronary heart disease among Pacific Island people in New Zealand. NZ Med J 103:448–449, 1991
    OpenUrl
  7. ↵
    Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497, 2001
    OpenUrlCrossRefPubMedWeb of Science
  8. ↵
    Hu G, Qiao Q, Tuomilehto J, Balkau B, Borch-Johnsen K, Pyorala K, DECODE Study Group: Prevalence of the metabolic syndrome and its relation to all-cause and cardiovascular mortality in nondiabetic European men and women. Arch Int Med 164:1066–1076, 2004
  9. ↵
    Anand SS, Yi Q, Gerstein H, Lonn E, Jacobs Ruby, Vuksan V, Teo K, Davis B, Montague P, Yusuf S: Relationship of metabolic syndrome and fibrinolytic dysfunction to cardiovascular disease. Circulation 108:420–425, 2003
    OpenUrlAbstract/FREE Full Text
  10. ↵
    Park Y, Zhu S, Palaniappan L, Heshka S, Carnethon M, Heymsfield SB: The metabolic syndrome: prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey, 1988–1994. Arch Int Med 163:427–436, 2003
    OpenUrl
  11. ↵
    Meigs JB, Wilson PW, Nathan DM, D’Agostino RB Sr, Williams K, Haffner SM: Prevalence and characteristics of the metabolic syndrome in the San Antonio Heart and Framingham Offspring Studies. Diabetes 52:2160–2167, 2003
    OpenUrlAbstract/FREE Full Text
  12. ↵
    Jaber LA, Brown MB, Hammad A, Zhu Q, Herman WH: The prevalence of the metabolic syndrome among Arab Americans. Diabetes Care 27:234–238, 2004
    OpenUrlAbstract/FREE Full Text
  13. ↵
    Resnick HE: Metabolic syndrome in American Indians. Diabetes Care 25:1246–1247, 2002
    OpenUrlFREE Full Text
  14. ↵
    Jeong SK, Nam HS, Rhee JA, Shin JH, Kijm JM, Cko KH: Metabolic syndrome and ALT: a community study among adult Koreans. Int J Obes Relat Metab Disord 28:1033–1038, 2004
    OpenUrlCrossRefPubMedWeb of Science
  15. ↵
    Tan C, Ma S, Wai D, Chew S, Tai E: Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 27:1182–1186, 2004
    OpenUrlAbstract/FREE Full Text
  16. ↵
    Swinburn BA, Ley SJ, Carmichael HE, Plank LD: Body size and composition in Polynesians. Int J Obes Relat Metab Disord 23:1178–1183, 1999
    OpenUrlCrossRefPubMedWeb of Science
PreviousNext
Back to top
Diabetes Care: 27 (12)

In this Issue

December 2004, 27(12)
  • Table of Contents
  • About the Cover
  • Index by Author
Sign up to receive current issue alerts
View Selected Citations (0)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes Care.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Prevalence of the Metabolic Syndrome Among Adult New Zealanders of Polynesian and European Descent
(Your Name) has forwarded a page to you from Diabetes Care
(Your Name) thought you would like to see this page from the Diabetes Care web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Prevalence of the Metabolic Syndrome Among Adult New Zealanders of Polynesian and European Descent
David Simmons, Colin F. Thompson
Diabetes Care Dec 2004, 27 (12) 3002-3004; DOI: 10.2337/diacare.27.12.3002

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Prevalence of the Metabolic Syndrome Among Adult New Zealanders of Polynesian and European Descent
David Simmons, Colin F. Thompson
Diabetes Care Dec 2004, 27 (12) 3002-3004; DOI: 10.2337/diacare.27.12.3002
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • RESEARCH DESIGN AND METHODS
    • RESULTS
    • CONCLUSIONS
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Tables
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Overweight and Components of the Metabolic Syndrome in College Students
  • Improving Quality of Care in Diabetes Through a Comprehensive Pharmacist-Based Disease Management Program
Show more Brief Report

Similar Articles

Navigate

  • Current Issue
  • Standards of Care Guidelines
  • Online Ahead of Print
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Care Print ISSN: 0149-5992, Online ISSN: 1935-5548.